Immunocore Adds a PRAME Engager to Kimmtrak in Uveal Melanoma
- At SITC, Immunocore presented early Phase 1/2 data pairing brenetafusp, its PRAME-directed T-cell engager, with Kimmtrak in metastatic uveal melanoma.
- Roughly two dozen patients received the combination, with a similar number on brenetafusp alone.
- The company plans a randomized Phase 2/3, DUET-UVEAL, in HLA-A*02:01-positive patients.
💡 Points Based on public reports
Kimmtrak is the only approved therapy in this disease, so the combination is Immunocore defending its own franchise as much as expanding it. With under 30 patients and no randomized control, the data say little about added toxicity or benefit over Kimmtrak alone; DUET-UVEAL is where that is decided. It also tests PRAME engagers beyond cutaneous melanoma, where the first Phase 3 is under way.
#SITC26: Immunocore reports early data for brenetafusp plus Kimmtrak in uveal melanoma ↗